Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

A Study of RO7821657 in Participants With Solid Tumors

13 november 2026 bijgewerkt door: Hoffmann-La Roche

A First In-Human, Multicenter, Phase I Clinical Study of RO7821657, a Protease Activated TCB Antibody That Targets CEACAM5, in Participants With Locally Advanced and/or Metastatic Solid Tumors

The aim of this study is to characterize the safety and tolerability of RO7821657, describe its pharmacokinetics (PK), and evaluate pharmacodynamic and biomarker effects to support selection of the recommended Phase 2 dose(s) (RP2D[s])

The study consists of two parts, namely Part 1 and Part 2:

Part 1: Evaluation of RO7821657 as monotherapy in participants with microsatellite-stable (MSS) colorectal cancer (CRC).

Part 2: Evaluation of RO7821657 as monotherapy in participants with non-squamous non-small cell lung cancer (NSCLC)

Studie Overzicht

Toestand

Werving

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Geschat)

405

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: Fastest response: use the inquiry form. No email attachments. https://www.gene.com/contact-us/submit-medical-inquiry

Studie Contact Back-up

Studie Locaties

      • København Ø, Denemarken, 2100
        • Werving
        • Rigshospitalet
      • Sutton, Verenigd Koninkrijk, SM2 5PT
        • Werving
        • Royal Marsden Sutton

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Life expectancy estimated by the Investigator to be ≥12 weeks.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1.
  • Presence of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; previously irradiated lesions are considered measurable if progression has been demonstrated in such lesions after the irradiation.
  • Availability of archival tumor tissue or tissue obtained from a fresh biopsy at screening if formalin-fixed paraffin-embedded [FFPE]-preserved archival tissue is not available. The archival tumor tissue should come from a core biopsy, a punch biopsy, an excisional biopsy, or a surgical specimen. Lymph node biopsy, bone biopsy (unless from soft tissue), or fine needle aspiration are unacceptable for submission. Lesions that are intended to be biopsied should not be counted as target lesions.
  • Adequate cardiovascular function:

New York Heart Association (NYHA) Heart Failure Class ≤ 1.

  • Agreement to adhere to the contraception requirements.

Exclusion Criteria:

  • Participants with active Central Nervous System (CNS) metastases.

  • Any unresolved toxicities from prior therapy, i.e., radiotherapy, chemotherapy, targeted or checkpoint inhibitor therapy or surgical procedure, greater than CTCAE Grade 1 at the time of starting study treatment, except for alopecia and Grade 2 neuropathy.

    a) Stable endocrine AEs managed with hormone replacement are permitted, including hypothyroidism on stable thyroid hormone replacement.

  • History of interstitial pulmonary disease, drug-induced pneumonitis, or evidence of active pneumonitis on screening computed tomography (CT) scan.

  • Participants with pulmonary miliary metastatic pattern (innumerable small lesions) or pulmonary lymphangitic carcinomatosis.

  • Active autoimmune disease that has required systemic treatment (except replacement treatment) within the last 2 years or any disease requiring immunosuppressive therapy while on study.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Sequentiële toewijzing
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Part 1A: Dose Escalation

Participants with MSS CRC will receive multiple doses of RO7821657 in single and multiple participant cohorts.

Participants will receive RO7821657 as per the schedule described in the protocol.

Experimenteel: Part 1B: Backfill Cohorts

Participants with MSS CRC will receive RO7821657 at dosing regimen selected based on data from Part 1A.

Participants will receive RO7821657 as per the schedule described in the protocol.

Experimenteel: Part 1C: Dose Expansion/Optimization

Participants with MSS CRC will receive RO7821657 at dosing regimens selected based on data from Parts 1A and 1B.

Participants will receive RO7821657 as per the schedule described in the protocol.

Experimenteel: Part 2A: Abbreviated Dose Escalation

Participants with non-squamous NSCLC will receive multiple doses of RO7821657 in multiple participant cohorts.

Participants will receive RO7821657 as per the schedule described in the protocol.

Experimenteel: Part 2B: Dose Expansion/Optimization

Participants with non-squamous NSCLC will receive RO7821657 at dosing regimen selected based on data from Part 2A.

Participants will receive RO7821657 as per the schedule described in the protocol.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Part 1: Incidence and Severity of Adverse Events (AEs)
Tijdsspanne: Up to approximately 27 months

AEs will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Any events of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded based on the American Society for Transplantation and Cellular Therapy (ASTCT) criteria

Up to approximately 27 months
Part 2: Incidence and Severity of Adverse Events (AEs)
Tijdsspanne: Up to approximately 27 months

AEs will be graded according to NCI CTCAE v5.0. Any events of CRS and ICANS will be graded based on the ASTCT criteria

Up to approximately 27 months
Part 1A: Nature and Frequency of Dose-limiting Toxicities (DLTs)
Tijdsspanne: From Cycle 1 (C1) Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
From Cycle 1 (C1) Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
Part 2A: Nature and Frequency of DLTs
Tijdsspanne: From C1 Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
From C1 Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
Parts 1A and 1B: Recommended Phase 2 Dose (RP2D) Range of RO7821657
Tijdsspanne: Up to approximately 27 months
Up to approximately 27 months
Part 2A: RP2D Range of RO7821657
Tijdsspanne: Up to approximately 27 months
Up to approximately 27 months

Secundaire uitkomstmaten

Uitkomstmaat
Tijdsspanne
Parts 1 and 2: Serum Concentration of RO7821657
Tijdsspanne: Up to approximately 27 months
Up to approximately 27 months
Parts 1 and 2: Objective Response Rate (ORR)
Tijdsspanne: Up to approximately 27 months
Up to approximately 27 months
Parts 1 and 2: Disease Control Rate (DCR)
Tijdsspanne: Up to approximately 27 months
Up to approximately 27 months
Parts 1 and 2: Duration of Response (DoR)
Tijdsspanne: Up to approximately 27 months
Up to approximately 27 months
Parts 1 and 2: Progression-free Survival (PFS)
Tijdsspanne: Up to approximately 27 months
Up to approximately 27 months
Parts 1 and 2: PFS Rate
Tijdsspanne: At 6 months
At 6 months
Parts 1 and 2: Overall Survival (OS) Rate
Tijdsspanne: At 6 months
At 6 months
Parts 1 and 2: Correlation of Baseline Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Tumor Expression With Clinical Activity
Tijdsspanne: Up to approximately 27 months
Up to approximately 27 months
Part 1B: Cluster of Differentiation 8 (CD8) Expression in Tumor Tissue
Tijdsspanne: Up to approximately 27 months
Up to approximately 27 months
Parts 1C and 2B: Percentage of Participants With Presence, Frequency, Severity and Interference of Symptomatic Treatment Toxicities as Assessed by NCI Patient-reported Outcomes (PRO)-CTCAE
Tijdsspanne: Up to approximately 27 months
Up to approximately 27 months
Parts 1C and 2B: Change From Baseline in Symptomatic Treatment Toxicities as Assessed by NCI PRO-CTCAE
Tijdsspanne: Up to approximately 27 months
Up to approximately 27 months
Parts 1C and 2B: Percentage of Participants Troubled by Treatment Symptoms, as Assessed by Single Item European Organisation for Research and Treatment of Cancer Item Library 46 (EORTC IL46)
Tijdsspanne: Up to approximately 27 months
Up to approximately 27 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Clinical Trials, Hoffmann-La Roche

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

10 november 2026

Primaire voltooiing (Geschat)

31 mei 2030

Studie voltooiing (Geschat)

31 mei 2030

Studieregistratiedata

Eerst ingediend

14 oktober 2026

Eerst ingediend dat voldeed aan de QC-criteria

14 oktober 2026

Eerst geplaatst (Werkelijk)

20 oktober 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

16 november 2026

Laatste update ingediend die voldeed aan QC-criteria

13 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • BP46447
  • 2026-526150-14-00 (Ctis)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren